On October 14, 2025 Caris Life Sciences (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, reported it will unveil six studies at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2025, in Berlin, Germany from October 17-21, 2025. These presentations highlight the transformative power of multiomics, a scientific approach that integrates data from multiple biological layers to achieve a comprehensive understanding of biological systems and disease. The research spans nine tumor types, and results showcase how integrated profiling, subtyping, and biomarker discovery are driving more informed treatment decisions and improving patient outcomes.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The six studies were conducted in collaboration with more than 25 leading cancer centers across the U.S., Europe, and Japan, including members of the Caris Precision Oncology Alliance. The research will be featured across multiple formats, including one oral "Proffered Paper," one mini-oral and four poster presentations. The studies highlight Caris’ continued leadership in applying next-generation sequencing (WES and WTS), immunohistochemistry (IHC) and real-world clinico-genomic data to uncover actionable insights. Tumor types represented include colorectal, gastric, breast, pancreatic, head & neck, prostate, urothelial, renal, and biliary tract cancers.
"By integrating real-world data, advanced sequencing and biomarker discovery, we’re refining cancer subtyping and treatment decisions to improve patient outcomes across numerous cancer types,’ said Milan Radovich, PhD, Senior Vice President and Chief Scientific Officer at Caris. "ESMO provides an international stage to share these insights and accelerate the future of personalized cancer care."
Oral ‘Proffered Paper’ includes:
The Mechanism of Mismatch Repair Deficiency (MMRd) Informs Survival Outcomes Derived from Immune Checkpoint Blockade (ICB) Across MMRd Solid Tumors (Presentation Number: 1110)
Saturday, Oct 18, 2025
Mini-oral includes:
Comprehensive Multi-Omics Analysis of Early-Onset Cancer: Insights from the MONSTAR-SCREEN-2 Experience (Presentation Number: 115MO)
Saturday, Oct 18, 2025
Posters include:
Impact of Androgen Deprivation Therapy (ADT) on KLK2 mRNA Expression and Immunologic Correlates Across Prostate Cancer Disease States (Presentation Number: 2437P)
Saturday, Oct 18, 2025
Optimizing Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer Through Tailored, Subtype-Specific Treatment Approaches (Presentation Number: 795P)
Sunday, Oct 19, 2025
Transcriptomic-Based Prediction of Therapeutic Response in Metastatic RAS-Mutant Colorectal Cancer (Presentation Number: 829P)
Sunday, Oct 19, 2025
NOTCH: A Dynamic Pathway in Head and Neck Squamous Cell Carcinoma (Presentation Number: 1409P)
Monday, Oct 20, 2025
The full abstracts will be available on the Caris website at the event’s conclusion.
The Caris Precision Oncology Alliance (POA) consists of 97 cancer centers, academic institutions, research consortia and healthcare systems, including 45 NCI-designated cancer centers, all collaborating to advance precision oncology and biomarker-driven research. Caris and POA members collaborate to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers, aiming to improve clinical outcomes for cancer patients.
(Press release, Caris Life Sciences, OCT 14, 2025, View Source [SID1234656655])